Heinz-Josef Lenz
Cited by
Cited by
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ...
autophagy 17 (1), 1-382, 2021
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
A Grothey, E Van Cutsem, A Sobrero, S Siena, A Falcone, M Ychou, ...
The Lancet 381 (9863), 303-312, 2013
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
MJ Overman, R McDermott, JL Leach, S Lonardi, HJ Lenz, MA Morse, ...
The lancet oncology 18 (9), 1182-1191, 2017
Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer
MJ Overman, S Lonardi, KYM Wong, HJ Lenz, F Gelsomino, M Aglietta, ...
Journal of clinical oncology 36 (8), 773-779, 2018
Randomized trial of TAS-102 for refractory metastatic colorectal cancer
RJ Mayer, E Van Cutsem, A Falcone, T Yoshino, R Garcia-Carbonero, ...
New England Journal of Medicine 372 (20), 1909-1919, 2015
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
AF Sobrero, J Maurel, L Fehrenbacher, W Scheithauer, YA Abubakr, ...
Journal of clinical oncology 26 (14), 2311-2319, 2008
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
D Salonga, KD Danenberg, M Johnson, R Metzger, S Groshen, ...
Clinical Cancer Research 6 (4), 1322-1327, 2000
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation–a target for novel cancer therapy
R Tokunaga, WU Zhang, M Naseem, A Puccini, MD Berger, S Soni, ...
Cancer treatment reviews 63, 40-47, 2018
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer
EV Cutsem, HJ Lenz, CH Kohne, V Heinemann, S Tejpar, I Melezínek, ...
Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors
PG Johnston, HJ Lenz, CG Leichman, KD Danenberg, CJ Allegra, ...
Cancer research 55 (7), 1407-1412, 1995
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six …
D Arnold, B Lueza, JY Douillard, M Peeters, HJ Lenz, A Venook, ...
Annals of oncology 28 (8), 1713-1729, 2017
ERCC1 and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy
Y Shirota, J Stoehlmacher, J Brabender, YP Xiong, H Uetake, ...
Journal of Clinical Oncology 19 (23), 4298-4304, 2001
Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a …
AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, B Fruth, JA Meyerhardt, ...
Jama 317 (23), 2392-2401, 2017
The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer
MM Pomerantz, N Ahmadiyeh, L Jia, P Herman, MP Verzi, ...
Nature genetics 41 (8), 882-884, 2009
Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials
S Tejpar, S Stintzing, F Ciardiello, J Tabernero, E Van Cutsem, F Beier, ...
JAMA oncology 3 (2), 194-201, 2017
Activity of sunitinib in patients with advanced neuroendocrine tumors
MH Kulke, HJ Lenz, NJ Meropol, J Posey, DP Ryan, J Picus, E Bergsland, ...
Journal of Clinical Oncology 26 (20), 3403-3410, 2008
Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy
ST Pullarkat, J Stoehlmacher, V Ghaderi, YP Xiong, SA Ingles, A Sherrod, ...
The pharmacogenomics journal 1 (1), 65-70, 2001
ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil …
R Metzger, CG Leichman, KD Danenberg, PV Danenberg, HJ Lenz, ...
Journal of Clinical Oncology 16 (1), 309-316, 1998
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret …
AA Garcia, H Hirte, G Fleming, D Yang, DD Tsao-Wei, L Roman, ...
Journal of Clinical Oncology 26 (1), 76-82, 2008
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines
HJ Lenz, E Van Cutsem, S Khambata-Ford, RJ Mayer, P Gold, P Stella, ...
Journal of Clinical Oncology 24 (30), 4914-4921, 2006
The system can't perform the operation now. Try again later.
Articles 1–20